Viking Therapeutics (VKTX) 13 Mar 192018 Q4 Earnings call transcript

Good afternoon and welcome to the Viking Therapeutics' Fourth Quarter 2018 and Year-End Earnings Conference Call. [Operator Instructions] Please note, this event is being recorded. I would now like to turn the conference over to Stephanie Diaz, Investor Relations. Please go ahead.

Hello and thank you, all, for participating in today's call.

Brian President President of is Michael CEO; today Vice Morneau, Finance me Lian, and Viking's and Joining and Administration.

undertakes I'd no differ call involve of statement uncertainties. these company XXXX, the current begin, Securities Brian? during to a the for Securities within revise encourage number these we to turn like any the statements of Commission of and the from XXXX, that obligation or update of I'll results caution Actual Lian Before concerning of comments now his filings the this the meaning made you conference initial concerning and and contain matters. and the today, assumptions, Exchange with I will call comments. today. XX, beliefs other risks Brian Act the March over could forward-looking statements to review all made company's to company which

as of demonstrating receptor results This sufficient in to and a study listening Stephanie, thyroid yield This X after Phase trial by androgen program VKXXXX, everyone in support XX nonalcoholic These of agonist, Thanks, best-in-class significant its data for the well Last webcast fat setting Phase I'll primary pipeline dosing. pipeline of in endpoints, disease. year novel with novel decision weeks advance and progress we this data and of to accomplishments, reported update XXXX patients our compelling our NASH. its and additional lipids we receptor to In as efficacy our thanks September, two evidence an of in XXXX VKXXXX's X of the further Today, featured a as both and presentations muscle our our raised this non-alcoholic achieved an successfully trial growth announced frail hip XXXX, VKXXXX as of development an or operations. the recovering capital hypercholesterolemia fatty beta VKXXXX from we VKXXXX secondary to plasma the from a Underscoring on of was phone. of and also and safety update population. conferences steatohepatitis their reductions programs our our modulator programs as or proceed in areas. points. provide liver important results secondary related selective value in endpoints, on was effect data clinical podium importance key Viking pivotal recent patients two fracture. these primary of and well potent VKXXXX to on developments studies each clinical programs, inflection from at the study international liver in and and provide the with demonstrating both respective statistically of achieved our

results VKXXXX's featured a liver stage major earlier presentation at reducing podium inflammatory demonstrating conference promise in in third September. addition, fat and in In markers were a

financial to of the now resulted of productivity our over competitors We the review and of year on support to able and like sheet enthusiasm are at pipeline development turn but significantly discuss first programs, common our proceeds they financials. Finance $XXX that comments in programs I'll accomplishments, total the stock Vice many these that and fourth quarter XXXX own in Mike? stage XXXX additional as results. Michael pipeline success offerings Viking in through Morneau, to call Viking's excess I'll to provide gross and President received of we of validate million. on our differentiates balance from of Based our our view the in our Administration full we'd depth, recognition to for were the biopharmaceutical events our our proud space. have strengthen our our quality

like details. I'd I comments now for December my filing additional with refer conjunction fiscal to year today go the Commission with expect Exchange that to which later Viking's In XXXX. participants of I'll results XX end the find recommend quarter and Brian. XX-K on Securities to Thanks financial fourth for the

XXXX a the expenses Our clinical million for period study research third-party to three same consultants and months compensation, expenses. of The use offset expenses our preclinical ended development million stock-based December to drug increased study $X.X were and due of primarily was XXXX. decrease efforts, increase in XX, the partially for candidates, by compared $X manufacturing to related

primarily XXXX. Our were salaries and fourth compared expenses. to to expenses to million and same increase compensation, legal increased general was due expenses $X million, related benefits, patent quarter The in and $X.X stock-based the period administrative for and

December income. loss primarily three by XXXX in For in partially XX, to at XXXX. the The offering. primarily the net XX, and offset increase per net of three $X.XX ended by The December corresponding increase the outstanding the loss months $X.X to of related a income million December per an expenses shares the a increase additional or loss share, December in through XXXX XX, reported due versus those XXXX XXXX, million primarily share the XXXX was outstanding months is per previously, net $X.XX during December additional in equity period issued development interest by decrease three ended noted share or XX, XX, compared to for $X.X the at in driven given company other increase XXXX Viking in shares the months research for the loss net ended in

in to preclinical the manufacturing related $XX.X development to XX the same million research third-party stock-based consultants, were increased compared and study drug compensation efforts, by a our partially in expenses. expenses period Our expenses clinical and primarily ended candidates December XXXX increase months related due XX, of for use is decrease study to $XX offset XXXX. The for million to

is related professional taxes. based services, XXXX. salaries of due expenses for ended million stock period and XX increase consultants, primarily and million administrative insurance, and increased XX, same December third were benefits, The $X.X expenses $X.X use compared general months the competition, XXXX expenses, Our the party to legal to for in patent to franchise

an loss December XXXX, per reported per Viking corresponding million for December of to net in ended increase for noted net net interest income an XX XX, increase by months a driven conversion of the XX, $X.XX The the December by the XX period in primarily expenses XXXX. the to loss share outstanding XXXX. XXXX increase loss shares December research a is $X.XX or or to income. XXXX XX, share the expenses in fair development the months million share ended well in compared decrease debt in For $XX.X loss of XXXX at related and offset as was previously liability net decrease as versus XX, at months primarily the outstanding general additional in per The XX, value XX increase in administrative feature December $XX.X at in due the those and

Given issued equity by XXXX public offerings. the additional shares the primarily company during through

at XXXX $XXX.X and cash Our investments equivalents, balance sheet cash, million. totaling showed XX, December

my XX, stock turn XX,XXX,XXX back February call of As review. Brian. concludes XXXX,Viking to common over the has financial shares outstanding. now I'll of This

founded pipeline of Thanks with a a small advancing of molecules. promising Mike. mission was Viking

selective investors, of the of support financial fortunate as same maximize resources necessary trial with XXXX, and the most benefit it receptor we unmet proof-of-concept Our is endocrine Phase their from in clinical our outcome conduct from have establish promising parallel modulator, the to programs. androgen to of to late programs our today in high a reported in studies these X recovering that with positive the to novel has need. In to maximizing patients surgery. receive been. VKXXXX, metabolic fracture a value we With goal been hip from areas is And always patients

Phase XXXX patients demonstrated a study preparing the produce mass trials VKXXXX, outcome by the this with success results efficacy this in with the a and therefore in for liver follow to initial completion trial disease. excited receptor this and measures. setting program. agonist evidence our next these this discussed of X and We The previously primary as of successful patients improvement advance of As compelling year in of to fatty VKXXXX provide are novel past we hypercholesterolemia in were secondary steps muscle beta significant thyroid of the achievement in VKXXXX

a VKXXXX of for the potential beta possesses steatohepatitis in range a well agonist lipid orally as liver non-alcoholic is or promising thyroid available selectivity tissue the hormone an of receptor including that as As disorders receptor therapeutic reminder subtype NASH. suggesting

oral assessed evaluated of The milligram every XX of milligrams or patients Our endpoint, study compared to that the of placebo trials effect receive cholesterol. successfully to patients Phase placebo placebo double-blind XX in endpoints. results reductions primary to controlled fatty doses with elevated change proton VKXXXX endpoint MRI and VKXXXX compared to X non-alcoholic weeks. day primary was to LDL of significant liver XX or fat both tolerability the point VKXXXX with on achieved end after We randomized parallel the that and statistically trial day other the secondary VKXXXX for fat disease trials and placebo weeks the designed a fall were as in report weeks. XX efficacy, VKXXXX every primary randomized Patients its study treated XX LDL by With group safety, secondary pleased were the demonstrated evaluate and evaluated very and receiving respect last experienced patients. liver fraction density LDL after

proteins, improvement in b other patients including In lipoprotein-a. apolipoprotein- and experienced addition atherogenic and treated significant lipids VKXXXX the statistically triglycerides

the in was assessed liver the liver The On response patients today. fat secondary significant point oral VKXXXX change development magnitude reduction in that receiving experienced fat content, agents by MRI-PDFF. of demonstrated results assessing end among the unprecedented of as

clinical differentiated doses This doses patients receiving of fat experienced approximately the every our milligrams liver patients included placebo Specifically relative reduction of to supports VKXXXX analysis, a more a have fat at the from dosed targeting threshold important treated efficacy improved they to of reduction patients broader among whether XX% liver liver analysis fat of fat reduction low that in receiving of This reduction histology if XX% when were with multiple XX% which liver liver patients XX% other liver approximately content. equal on may responder may receiving day content median trial every of patients a experienced Patients milligrams overall fat studies demonstrated reduced day reduction reduction with is XX in benefit. The a fat. a a in XX provide unique in relative day, in approximately experienced baseline. provide milligrams in relative increase fat level a doses observed median VKXXXX predict VKXXXX treated characterized XX% reduction therapeutic observed. XX median corresponding is or as at a milligrams for from also of experienced or VKXXXX baseline. relative view NASH. at that these comparison By assess by XX weeks experienced responders was features This interest which also liver as of greater from at XX% odds intended X%. suffering other demonstrated reduction Patients than in content. per benefit effects daily approximately in liver revealed fat content observed dosed liver is Among liver XX% approximately least that VKXXXX XX% least at XX fat

On or Turning there study. of randomized though adverse relatively to and overall across extremely to more events receiving in be arms distributed numerically this VKXXXX tolerated evenly be placebo. numbers this VKXXXX among were patients serious events was well adverse were among were to shown placebo. safety, to slightly VKXXXX reported study. was in shown well-tolerated safe treatment tolerability, patients No The

American of highlighted at presentation inclusion selected gratified importance We conference. on are Association we to the of part to demonstrated effects contributions Meeting Study Diseases efficacy AASLD. for opportunity to And have potent safety of in AASLD, particular Liver to have the late fourth the the Annual measures. the tolerability displayed and community light thus particularly these as quarter breaking results or oral the of in data of of encouraged which as were pharmacodynamic by our XXXX of the were report a honored the at this medical We the far, best for the

XX recall, you as an allowed day, patients was of milligrams study of randomized in and milligram efficacy every to XX expedite may this milligrams the and quickly us designed the the some enrollment cohort an focus This complete suspend and to VKXXXX milligram to effort four-arm weeks. elected study XX daily, XXXX placebo safety. XX completion receive in we doses daily, for the arms. on of obtain X study, VKXXXX's other study As or In a milligrams of with originally X understanding more promising to

of had completion we identified the for certain were milligram participating in enrollment that been Following subjects notified XX screening. by sites dosing additional cohorts,

in we data. to XX an to in result this collect we and cohort milligram and additional the resume half patients the additional a fourth six a Through the this for As XXXX, to efficacy X of of quarter milligrams order enrollment in X or randomized elected cohort dosing placebo. second expand in cohort XXXX, safety of enrolled total patients

received to of received analysis. milligram to the XX thus in initial fat this see patients and from least as and study. that baseline daily of patients in XX subjects XX a milligrams baseline as reported. results included relative reduction a VKXXXX XX study the post experienced other data baseline to we're to dosed follows: continued X randomized every subjects recently previously milligram X As a at a the dosing this efficacy were are the baseline lipid subjects when milligrams enrolled analyses We XX a and The XX%. are all the was from in reading had XX this show milligrams are All that analysis to pleased MRI result, arm day, safety to number the liver total in from in and low daily. these post XX to X included robust allocated X of has and included cohort lipid provide response and a XX XX XX randomized these and the MRI as to as randomized placebo, were the by increased milligrams of demonstrated Randomization daily, XX signal. patients study of

and fatty cohort our liver also prior the with reduced levels best-in-class possesses reported as VKXXXX VKXXXX efficacy, adverse addition, with patients tolerability ALT belief in consistent events relative and AST serious The in among disease. in displayed X-milligram placebo. the In XX-milligram profile with no cohorts, overall receiving were receiving were safety, to is patients that VKXXXX. patients

a further targeting enhancing future evidence the further the as Importantly, in of these therapeutic allow provides We at the may potent evaluation for data meeting for cohort submitted a results or selected European Association to of has upcoming this to effects week studies, were late presentation doses conference for poster for presentation we and the and Liver participate. Study conference. of We breaking opportunity late from liver last happy breaker that the even the that excited the notification at received lower been annual EASL, from molecules this to VKXXXX's NASH profile. abstract forward our as are this look

year, Xb the Looking ahead plan to of a biopsy-confirmed NASH. with the VKXXXX initiate in with second-half study patients we Phase in

of supporting pre-IND to this for data. our with FDA to preparation hold the study, and our discuss we the part As meeting clinical plans intend

FX the target that well FX While not regarding number been study anticipate and fibrosis details finalized, will as a with design limited we FX trial patients this fibrosis. have with as

dosing. We months of up more for XX expect dose the VKXXXX study to of than evaluate to one

detail results are motor program, believed further tissue. is a to long called X-ALD. agonist to now These a and molecule disease turn this to chain metabolism neuron benefit. receptor is showed to we tissue. which of chain and receptor plasma X-ALD. to of ABCDX. VKXXXX available thyroid very cerebral therefore characterized commonly may are disease. in Krieger levels potential defect orally providing study improvement acids, molecule animal in fatty to beta move completed for a disease thyroid that Kennedy and in selectivity at a is our notably, accumulation of in chain plasma peroxisomal fatty late small very the I'll or promising our this in the the effects markers X-Linked initiation. devastating observed therapeutic evaluating subtype model long collaborators in a disease, study approach the transporter and acids the In as long Viking's both an of VKXXXX fatty severe caused elevations represent provide very chain patients acids treatment The for adrenoleukodystrophy XXXX, acid closer by very possesses Sustained about beta of by an potential Activation an contribute on XX-week fatty the the thyroid long disease. the is and Institute a believed we often agonist stimulate X-ALD toxicities small orphan receptor will We receptor of evaluating pharmacologic potential VKXXXX and a study as

to VKXXXX to conducting skin concept prostate. androgen receptor in file a an and to our initiate currently designed are We of modulator is and novel proof plan disorders. this muscle work tissues reduced with for peripheral on and program selectively activity such bone formation, an in I'll humans. now for study selective musculoskeletal IND-enabling update provide VKXXXX, stimulate IND as

to refracture VKXXXX increases repair of surgery placing at of formation Multiple muscle fracture, these Following them rates, health and an thereby compared significant at for of patients represent with and line X Top that endpoint, VKXXXX studies our accelerated to disability. bone may and by the increased muscle patients from from recovering the its hip important improving statistically less patients demonstrating mass experience Phase a primary risk in musculoskeletal placebo. that loss treatment treatment successfully following demonstrated trial have achieved many option bone, stimulating morbidity, and further data as prolonged lean injury. dependent the head, facilitating in from body dose hip fracture study recovery showed

powered numerical trends though endpoints treatment In assessing addition, showed for function significance, favoring not arms. physical

meeting ASBMR. annual with September from events at XXXX, at for encouraging invited Mineral data tolerability the study were In Society safety this session the oral adverse American and in Research Importantly, Bone to of plenary or we the also and this present no demonstrated study reported. VKXXXX drug-related serious

Conference have organizers. Most need population. received Abstract the this fragile honored ASBMR the award for the by important preservation findings significant highlighted in event our were believe speaks also We Clinical to and we abstract at the award to Outstanding Our this musculoskeletal

in quarter more receive exploring where into in fracture challenging XXXX, potential efforts regulatory feedback path disability. to on expected play We pursue we for disease in VKXXXX VKXXXX hip orphan role make may the registration believe the third progression a indications, the the of U.S., development fracture recent potential muscle have our of the it from study. in hip During clinical the regarding benefit as impaired the and such focused FDA endpoints further

pursue intend and current as settings conducting potential prior clinical activities the updates Our is forward. to on orphan opportunities We'll to these licensing additional well for partnering as as both orthopedic studies. warranted provide moving

or stage other due XXXX, to on necessary with in the in multiple progress of updates; we well Viking. corporate in XXXX clinical $XXX these reviewed we balance their other and significantly large programs. continued to the and to forums. we've front, and support XXXX, VKXXXX. part with In from to we clinical as our results data recognized be the In and excited our sheet research investors of financial more conduct than Moving strengthen are the financial None our earlier positive are progress for our programs were made providing execute million, trials runway analysts without conclusion, VKXXXX achieved resources with we raised to work we as program possible would to able grateful in VKXXXX have our gratified peer

an the VKXXXX Vienna. in later presentation and remain track look IND in eager initiate NASH in to Phase year. for forward We at upcoming and study to this EASL a our this Xb progress biopsy-confirmed We to continue conference XXXX file are on

It to in year is an important our make IND this us half in VKXXXX IND also the bring X-ALD. second into our to development. to allow potential for clinical therapy progress continue file the We to goal work with of

look we to matures, programs also disorders. with metabolic of our pipeline stage targeting earlier some progress our making and lipid As forward

concludes We Operator? comments open now will This And questions. share today. they updates for to for the as us. our joining like relevant Thanks for available. become prepared call again I'd

Steven James. Raymond Our with [Operator ahead. first question from Seedhouse comes Please Instructions] go

in did or you Brian, milligram than correct, is say all were fat patients I content? greater of responded so X heard liver just to had XX that in XX, clarify you reduction XX% that

That MRI, patient a additional who second of - did X All XX. are randomized the of receive did was the there who not is one at look them. and the placebo a One one XX not one of you so VKXXXX MRI. get second when

adverse NASH here And seems be in There events I of scrutiny just and AEs X VKXXXX. amongst study. the study want to X, investors Phase some also intercepts and ask uncertainty to of actually about similar Phase

I of in treatment to you've were study obviously the now right imbalance AEs. either any think topical is you if arms the emergent but or I was any AEs clarify with emergent serious the there in space. in or hepatobiliary this or pretty across milligrams AEs treatment no milligrams arms study? in So across there reported today hepatic related update Could cardiovascular X great any the treatment just the or XX Phase in that in emergent treatment my question separately just believe X AEs

X we the yet. mg recently just were received. So patient The from data don't arms patient the have efficacy all data by of

we'll getting EASL. should month safety think before data be later this I be the

trends of highest in numbers, was my to the don't Well, in So not just going the major top arms. overall arm them are that the and VKXXXX weren't I treatment be placebo to to emergent receiving emergent treatment with just adverse the no have lot off adverse there emergent. associated recall I'm treatment head. give the serious any events, of There in granularity treatment a not and able number event I grade Yeah.

all So I far into can the don't in know about of get data if the too I hand. details

mentioned the Maybe to end at you just arm, turning call the indications of orphan this exploring some there. VKXXXX

the in experts and worth Stephen high some pretty mechanism out data folks the promising pursuing but looks in XX% patients profile novel, just or this and about reduce it also saying field actually related fat that yeah, are drug press essentially oral recent for and are like there further. ALT and Sanyal are XX% and in that Arun data liver Harrison, an testosterone mechanism So by some can releases in reduces the

the of or see So have entertain in molecule I'm you you've if there NASH? Obviously idea that MRI-PDFF XX-week ever study SARM. wondering just NAFLD to a your running with if anything you have

fat It's was look can a receptor saw at we composition support content, And body pretty it in XX-week and cool that the the is think the that's to thesis those see they and when you we're no. would to a gain which a, data but really in I really we interesting and that mean that leaning. the answer to I certain thought the the But, know some activate I study, reported you prior pursue in But really near being androgen approach interesting actually saw not term, reduction it's especially when going the question. is interesting subpopulations. that's you you a in muscle to that

Are dosing And some just after reached weeks even you measurements to metrics days presented already if or state, going weeks cleared make around know a that's data? have I you two or here you're to for ones on it it four VKXXXX just to think sure is if the think what's X want what liver steady the ASOBs mean, wrap the in so a few you half-life I is pretty I … does I I'm the show hang and interpreting have XX-week quickly you not study. you've going you - after - maybe so. X that do if stopped And in quick to up know so, XX-week MRI Phase is -

Yes.

So…

drug context in levels data correctly? so, of the …

XX don't day So and XX-week that. other believe ever to I recall ever back have I seeing think XX have half-lives, do daily. mistaken the check be I could don't data determined, we specific don't that go the but have I We every and I mg the was tissue from mg but

we'll in if end but will think month include next I'm getting the will. have EASL the positive data mg not of in that but the we hopefully at X we possible XX-week or be that presentation, it, I the the would month, early from the EASL,

me. for one Last

do there that question you the fair on Phase reports the and I from six-month is report concerned earnings those X so. guess absolutely those a or indicated GLP that were have the be your report arose late guess and XQ studies would I upcoming XQ the and studies in I last call either maybe the were filing I VKXXXX, you IND you was indication of study or that no So now road maybe that the for expected talks think early issues FDA? final primary

Yes. A critically of something important It's spending we're question. time a lot on.

study consistent as prevent detail guess planned. So Right around animal it meeting proceeding the us prior pre-IND consistent really nothing we've into that's a as lot going the our we're of we completed data Summertime the will that have And good the far a as the is go industry I'll standards not at we feel the I comments, this and studies with is next say the mid-summer. FDA now the timing as looks But the with as that's timing on There's should like. of and animal as human from today. of we're point. to aware well. all data to to give submit well

with Pantginis ahead. Joe from go Please comes H.C. question next The Wainwright.

partnering are any you your Thanks. develops? as as you indications discussions they part considering one, VKXXXX be and of of meeting you FDA number how can the know disclose co-promote might but guidance ahead interested the questions. and do and potential are before I still it's have for potential the to Two On of any then options VKXXXX, program being secondly any you your Phase types of going approximate decided size Xb

this some those today. other some On And would going from a be plays that's having how VKXXXX to muscular dystrophy orphan many say will VKXXXX the a could up on mechanism be With the the think obviously conversations size of the the and and it benefit of where program, in we that some the orphan driver of it don't of be arms would be of will know in XXX and I I be but exactly there science, from disability. a impairment we low-end might some are there. role opportunities robust of indications study and critical small muscle

hip regulatory future On side, think challenging made just in fracture the think U.S. for here I the I progress. path has the it,

more I there is but very Is think questions. a endpoints difficult looks potentially Europe, your clinical flexibility today. bit answers in on the that little in U.S. but it

Sorry.

that about desire your maybe the co-promote your for discussions discussions? to you part would part look potential in Just of have have to as partnering or the have option a optionality

allegations option. is think I everybody But just we disease has think, an XX progress we sit there we guess is so that always as mean, for that, a a mature smaller makes I today, company, the would I not that of difficult. here employees, realistic I treatment XX larger an certain in It's where it Maybe, indications, very be as could it something feasible employees, especially number option be today. is mean small have and specialized a centers but if that I a practical it's goes. that

Nash from comes SunTrust. next The with ahead. question Edward Please go

you question is try to to the X the duration is do remember clarify, months it is for just on Congratulations correct? and months, that study for for that milligram Edward XX daily. nine I Nash. mentioned And first Fang-Ke Huang This animal you is

six-month months a did the primate study ongoing a study. Well, the then and duration XX-month and six primate of was is study rodent we

trials you is in historically remind you just has the tested how other Phase one what potentially been lower second and in those us other see Can can the tested you tools in not maybe down can And dose you it got but low for be? what milligram natural that X trial, Xb. just mentioned tested

milligrams milligrams day So the Where we ranged see milligrams to more day. kind liver happening that clearly began the it really a X Phase you doses you the the Xb and of study, from of targeting five. is really X.XX efficacy see in and see kind the up XX above XX something would And this a X.X and of liver see to in efficacy day function a technology. to milligrams maybe

be and that X think mg, robust meg I to efficacy see think X to looking it suggest data. would say some so would fair at below the at I you hard otherwise argue certainly would

to I next want think the then, And about. one

in to the going Phase it be tough up can the You trial, to Xb a math. duration mentioned that

as shorter company an is going thinking improvement And trial the possible liver duration Phase in the and histology month? you for than think your to XX run think weeks. XX demonstrating Xb terms in they're the what of as do that current in start is short I

know a this you guidance months histologic the at, studies - current I prior has looking you're way calls short we're guess lot of there a benefit and been for looked have So right with at XX XX-month mechanisms a at is weeks. other as the nine biopsy. the as

know that still But establish suggesting to we're sufficient. mechanism generate if may you some is like the efficacy also are Now take XX and we meeting some thinking all time is to data maybe is signal. of now. some questions our little - that's of think of the true the bit anti-fibrotic more that clarity the of if likely I little right I about think when kind with And of to be would [indiscernible] nine ask endpoints months these you recommended that's this around better it duration. But the discussing something and a months pre-IND advisers in this to think

That makes sense. The sorry. last one, I'm

So VKXXXX, and own one also last is also and prodrug that deliver? is the targeted a around

So the it's plasma, not is in it's cleaved the that prodrug targeted a liver. to

need diffuse. prodrug by in reason you therefore so the started feels the we cleaved bit And technology. liver is targeted X-ALD and like not a necessarily that's looking specific it's just and little it's at it more So that disease deliver [indiscernible] don't that a

So phosphonic different acid. those said at and also also free it's that acid That phosphonic free very a salts very, look And looked interesting. we've different prodrug. of the

altogether. about bit it's selective, anywhere still a alpha, to So XX XX profile over little from beta X single It's it's more to different or got a animal just digit KI.

a work as it a potential really really, we compound know think hyperlipidemia X-ALD it think might So every know that could really, I future in work. place and think you interesting you I also

ahead. Hsieh question William Please The Andy comes from next with go Blair.

X do with and PK there dosing Could XX for a every to has significant difference question exposure profile. other the day milligram once first a milligram is us you the So day cohort? versus remind between

daily. actually other mgs it overall every than yeah the the But might with is look pretty Cmax the anyway you obviously similar that when means They're does mg is question? XX X day at higher your the with you expect but as answer

Yes.

question with has to So VKXXXX. the do second

date, the us Do pro-drug deliver also get strategy probably a X with reminding the and street asset is scientific inhibitor. Phase designed activated as a you program bisphosphonate rationale, to selectively familiar not and think I the bisphosphatase the know what's here? it website the mind - You fructose-X,X is this data on ready and you I this think generated said is

company. a original so very, what to is license was it's for it this for So, very the Viking - molecule special the Viking, is a VKXXXX,

study, So, is two to to It it very a step second those And It's would called hep held deciliter direct that X X% which fasting to is doesn't it - in fructose-X,X-bisphosphatase last XX in a in result - X.X% diabetics in mgs inhibits and a type were is if it it different up plasma to use glucose and enzyme a which robust highly reduction a the gluconeogenesis. XX-day in in I different endogenous think the translate XX-day study AXc. technology. reduction an pro-drug. statistically not shown into studies significant the per

aggressively it. haven't We been developing

the there for I effects. it company, hesitation fasting demonstrate explore we starting at AXC plasma be when of it the to really at molecule. XX-week glucose would were and the study point data And company the profile enthusiasm safety - think was I that from investors mechanism look the of that a to diabetes, some on think and it the for prior predicted X worthwhile small part our is diminish some provides reduction the to but type doesn't to

perspective, NASH address of partnership - strategic a possibility a I of of question with the syndrome of metabolic entertain and that from kind to you the the is setting Would related aspect the kind So be of would earlier. combining it of and just to kind to here out in question VKXXXX, guess so follow a Steve's up disease.

So, it's open back - door the for I always mean, it's here. a good question. is And go just second, a to

any table programs. So partnership of our is off not the for

So interested partners. opportunities with discussing we're always in

different than think And VKXXXX. in combinations as that game I that's patients, of NASH the might with we a As don't mean, And the about far combinations, right I I benefit make lot potential guess more sense. anything now. thought

Yale question Jen comes Please with next ahead. from Laidlaw Company. The go and

guys it's suggest going that a the to EASL present data and robust. you five you that my be that You enough Also meg of to sort data question at should robust is you the higher possibilities any and with dose, dose have in you of you things general? sort as the would maintenance those loading think such these guys contemplate regimen. subsequent a of can kind How about

question, That's lot a great thought We a about Yale. that.

given start low So for somebody dose for reduce higher a on if you sense. and months very you selectivity make potency that to liver the and example dose maintenance then a three know the might

the And of for so that one upcoming the just Xb we're Phase study. about it's elements thinking

answer smaller and We Xb. possible putting want decisions into know you've Phase haven't to that you study shorter that with fashion. a you timely final important and longer the any can there, question rather a we made small than But asked complete to it it's do keep in manageable enough an study a question

what economical way, potential payer of a benefit put regard you any see or patient let's regimen not that or in potentially of just sort or be or the do used benefit be sort can can payer this if the that's And considered?

low would the think generally favor patient I Well I know know doses. people you benefits think you

know think I at would all if generally it's initiating you pharmacy people not probably possible. favor

this you when something of be fibrotic thyroid the of reduction the of thyroid in we load, our the to benefits whole anti-fibrotic highest the a reduction associated of collagen are mechanism. beta see be a We I is presented patients. payer in think in We beta shown single at talk would resonate sounds signaling. at see overlook low dose a initial can range payers is sort the think people XXXX. own. well So in that of with that fibrotic it receptor. with It's you There fibrosis, a lot reduction it they a receptivity in a very When about going see benefits both of of clinicians like literature AASLD effective this know agent the and in to patients we we've studies activation multiple in and genes

fibrosis are beta going to a So looks a like be a benefit. payers notion a first that agent the incorrect think there And broader it eager thyroid the reimburse. is effect on agonist place metabolic just can just show data that the metabolic lot is most and if a is to I that you show than the benefit

regarding to X about size? of into patient early anything signals have VKXXXX more of one maybe or the look in to that or in so study efficacy question you now some is Do year next terms study sort you picture general very latest year having which talk going gauge Can And start X-ALD. Phase X you patients signal here probably X? that to potential Phase can start a you're Phase

into On patients. what XX sort study that dose single or transitions that ascending a into that say a day can so side in there dose the blends patient we is study multiple transitions of into ascending a

look know consider and next registration then might a acid begin you roll at something look ascending very we XX far-left long would to we get can would study you patients can you at very along capital dose start sort enough that And you And study fatty there. in. I so changes would as SAD study could get And be the far if your multiple potentially which of chain efficient as long one-stop efficient the there really. in that cohorts like We a very be days. see what you think some

or from the sample Where these the patients from plasma flown be other - tissues? will

just concept. demonstrate of well show would look at be It the way efficient to of plasma. would concept, proof That we easiest be the probably to proof most and the

ahead. Please go comes question next with Capital. Henry The ROTH from Scott

a couple of questions. Just

time VKXXXX as change could get to should about meeting. obviously to we Xb, the But patients? enroll XXX FDA we on First that Phase the start period both around the think some enrollment how parameters

So adjust of changes sites with enrollment the in commensurate any we'll number there.

look you think data. with when of timeline be know liver timeline trial enrollment by the size. I at there studies And the hope the larger we other would the that followed to some similar close to So is the of would histology would a out the size, we precedent you data and that for wash initial

been some there the some map that recent examples there allowed have know out. that in landscape So you - to you competitive

thinking we from sounds start change it like that think - be should time two could year a way about process about finish. table? Is about to greater reasonable the So things to

go we X to Hard initial the maybe more quickly possible recent took for on it's than study initiation and Phase think But fat from one about liver reading I that. know. example quarters to Well, to very seven five don't criteria before around were I time unreasonable again data frame. predict enrollment that's you to think six get But to until the an and hard available. the histology know identified. then size

bit up sounds And in R&D think the a XXXX, it how R&D, then obviously kind of it the of track perhaps QX we to in that mean the in about question, similar QX we XXXX? year biggest should QX, about modeling like I maybe trajectory when is should a for just beginning spike little for and the think lever

think I that's unreasonable. don't

for year then flattish the first and of the begin to up a think that's half statement, - a know half. the that's second in pick it's I should it fair You relatively

next David comes The from with Zack Investments. ahead. Bautz Please question go

players other So in the of in a from little a some competitive standpoint, you NASH. field are and bit the behind

Xb to So to made go a do trial? combined with and Phase the what decide and Xb/X you ultimately I'm wondering not Phase

fifth in timing the to made market. large I maybe don't fourth, as there out the taking in therapy the lag a and is examples third, being coming think of multiple as issue second, and or share an big are best it's of

sorts I So, with of development of rife examples. is history those think, drug the

vendors Phase feedback For Phase really the Phase and Phase in X KOLs from clinicians X of us the to standalone, the to and unanimous X/X the X/X. favor relative was in the comparing

very And rolls and away if - takes helped put multiple X, I've study, important you paper presumably cost the Phase patient no my several less the and got patients streamlined that we NASH trials this type that trial and saying, last And to us that heard was enrolling Xb. expensive times can heard this push And toward NASH X of for to Phase be Doc on savings. that really my enroll so a timeline would in if it the choose choice. wants that feedback despite a we to fact from Phase one to that

Mayank next FBR. Riley comes ahead. B. with from The question Please go Mamtani

and there End-of-Phase Just is class? framework back, when standpoint it are relative how a highest we dose have for the -- looks other X I words anything and taking mechanism you that the then thyroid couple margin asset, indication ratio or And have just from to different may about you agent that just you animal the looks in to hormone from I'm your have you that step level FDA obviously have the IND a more FDA me, different the at about in you the agonist. two that? humans, receptor high maybe in ever the groups talked meeting disclosed have advanced then mean also and for a assuming a what in tested safety that specific more your for do studies have

XX in animals where study exposure really effect know prior were levels would a Up the and humans animals to no in didn't observed. doses a be rodent adverse in levels to in exposure exposure little dose the an issue relate that really you and the proposed your say it was discuss to both of prior because adverse was propose have that level. how the events in high you primate the and the enough studies those I'll weeks bit go haven't. studies you We determine margin safety design whenever

was know So margin. to it with you just test the impossible

We would say I to of eliminate any higher dosing in question future margin. the evaluation substantially are that

for And question that I [really] think study. we so answer the next

and may evolved class the it FDA's level? how looked on has how comment view and at any at the maybe And that have historically FDA maybe

with and cartilage safety has less the We focus to issues agonists. associated the cardiovascular looked know the those with on selective thyroid class safety. are particular related FDA you And issues that known know at bone and

areas closely are studies of all know areas in at particularly particular those of those our to that and And we them look interest so are we

just And question minor one Phase X then the study. about

gets about looks think like window therapeutic you the every close dosing. the very day X the other you As mg it to

lot the similar to dose will or system if lower is sort an on thinking before commented to pay you do benefit be getting the would and it's the for of you get of you're which that value. the benefit anti-fibrotic and So, go therapeutic way just that go the where think

potentially? high You you as want to dose could as

if excellent it fat. Is you the dose that. Yes. improves. We downstream reduction don't I then XX% I dose know that all there higher example between know. And wouldn't same for argue fat with any a didn't fibrotic in benefit. of and is fibrosis different you know and of the we effects think some range. an But there have by the the dose. don't I question, might prior that are response we're you It's a and if there - a you liver No. reduce fat and benefit is between resolves liver I know don't fibrosis and when person's to. see answer now - that separation in for If answer. causing But body animal And fibrosis studies NASH that sort impact a in weight to this

is great some know. So I different a don't - question. there effects, but It's

with Palomeque Caroline Group. from ahead. Please comes question next Maxim Your go

you any and fibrosis safe endpoints - for you Phase approvable color is more if as on on far as could I'm resolution? focusing know to just you'll wondering the be give that XXXX the it protocol the assume Xb

at endpoints a exploratory host So I whole there. think of we would look

that fibrosis patients You fibrosis NASH know and NASH. proportion fibrosis know you worsening with the I I'm mean of of sorry. without an resolution some experience sorry I'm improvement in of who worsening

Yes. be would above in study. explored the of the All

a And on then pipeline. your question just

glycogen be in anytime that Just so wondering for moving the VKXXXX if clinic just into the storage soon. disease, will

think that I on the lot are focus and resources but in great a in future I of for and the indication question NASH some end NASH the it's near the indication. in promise No, year at of think We really company's our the towards a there's to revisit decided last maybe we most now today. view GSD term right effective could date focus

the concludes Stephanie This over like for our remarks. turn I back conference to Diaz question-and-answer session. closing any to would

look Therapeutics. you and have updating support months. of you continued very Thank again Thanks again your coming Viking participation in forward to and much great afternoon. the for We a

is conference today's The attending presentation. concluded. for you now Thank

disconnect. You may now